Shares of Oculis Holding AG (NASDAQ:OCS – Get Free Report) traded up 3.8% on Tuesday . The company traded as high as $15.17 and last traded at $15.17. 5,473 shares were traded during mid-day trading, a decline of 85% from the average session volume of 36,819 shares. The stock had previously closed at $14.62.
Analyst Ratings Changes
Separately, HC Wainwright reiterated a “buy” rating and issued a $30.00 target price on shares of Oculis in a research report on Monday, November 11th. Five research analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock currently has a consensus rating of “Buy” and an average price target of $29.20.
Check Out Our Latest Analysis on Oculis
Oculis Stock Up 3.6 %
Oculis (NASDAQ:OCS – Get Free Report) last posted its quarterly earnings data on Tuesday, August 27th. The company reported ($0.56) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.43) by ($0.13). Oculis had a negative return on equity of 71.31% and a negative net margin of 8,043.28%. The firm had revenue of $0.27 million during the quarter, compared to analyst estimates of $0.28 million. As a group, equities research analysts expect that Oculis Holding AG will post -2.09 EPS for the current year.
About Oculis
Oculis Holding AG, a clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic diseases. The company's lead product candidate is OCS-01, a topical dexamethasone optireach formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for dry eye disease; and OCS-05, a disease modifying neuroprotective agent for neurological damage with indications for glaucoma, dry age-related macular degeneration and diabetic retinopathy, and acute optic neuritis.
Read More
- Five stocks we like better than Oculis
- The Significance of Brokerage Rankings in Stock Selection
- Super Micro Computer Soars 28%: Is It Really Out of the Woods?
- How to Invest in Insurance Companies: A Guide
- Traders Are Flocking Back to Oil: What’s Fueling the Optimism
- TSX Venture Exchange (Formerly Canadian Venture Exchange)
- 3 Hot Stock Trends to Ride Into 2025
Receive News & Ratings for Oculis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oculis and related companies with MarketBeat.com's FREE daily email newsletter.
